Home › Encyclopedia › Substance P: Research Status and Clinical Trial Overview
Research / Unapproved

Substance P: Research Status and Clinical Trial Overview

Molecular formulaC63H98N18O13S
Molecular weight1347.6 g/mol
Registered trials1164
PubChem CID36511

What substance p is

Substance P is a neuropeptide studied in research settings, not an approved drug with a labeled use. It has the molecular formula C63H98N18O13S and a molecular weight of about 1347.6 (PubChem CID 36511). No regulatory label or approved indication exists for this compound.

Trial footprint

Substance P or related terms appear across 1,164 registered clinical trials, spanning a wide range of therapeutic areas rather than a single focused program. Among the sampled studies, a completed Phase 3 trial compared treatments for HIV-infected opioid and alcohol users in an integrated care effectiveness study. A Phase 2 trial of a neoadjuvant PD-1 vaccine in operable MSI-high colorectal cancer was terminated. A non-phase study examined a smartphone-based cognitive-behavioral intervention for depressive symptoms in caregivers and was completed. These examples illustrate the breadth of research contexts in which the term appears rather than a confirmed therapeutic pathway for substance P itself.

FAQ

Is substance P an FDA-approved drug?
No. Substance P has no approved label, brand name, or indication. It is referenced in research and clinical trial contexts, not as a marketed therapeutic.
What is substance P chemically?
It is a peptide with the molecular formula C63H98N18O13S and a molecular weight of approximately 1347.6. Its PubChem identifier is CID 36511.
How many clinical trials mention substance P?
Public trial registries list 1,164 studies associated with substance P. These span varied therapeutic areas and phases rather than one concentrated research program.
What kinds of trials have studied substance P?
Sampled trials include a completed Phase 3 study in HIV-infected opioid and alcohol users, a terminated Phase 2 colorectal cancer vaccine trial, and a completed non-phase behavioral health study. This range suggests substance P appears as a variable or reference point across diverse research, not a single approved therapeutic use.
Are there known side effects of substance P?
No adverse event report data is available for this compound in the data reviewed, so no side effect pattern can be summarized at this time.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 36511 ClinicalTrials.gov

Updated 2026-11-07